Vitamin D and Methylarginines in Chronic Kidney Disease (CKD)

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Oct 5

PMID 28976989

Citations 4

Authors

Claudia Torino

Patrizia Pizzini

Sebastiano Cutrupi

Rocco Tripepi

Giovanni Tripepi

Francesca Mallamaci

Carmine Zoccali

Affiliations

Soon will be listed here.

Abstract

Background: Vitamin D associates with the plasma concentration of the endogenous inhibitor of the nitric oxide system asymmetric dimethyl arginine (ADMA) and cross-sectional studies in CKD patients treated with the vitamin D receptor activator paricalcitol show that plasma ADMA is substantially less than in those not receiving this drug.

Methods: In the frame of a randomized, double-blind, placebo controlled trial, the Paracalcitol and ENdothelial fuNction in chronic kidneY disease (PENNY), we investigated whether vitamin D receptor activation by paricalcitol (2 μg/day x 12 weeks) affects the plasma concentration of ADMA and symmetric dimethyl arginine (SDMA) in 88 patients with stage 3 to 4 CKD.

Results: Paricalcitol produced the expected small rise in serum calcium and phosphate and a marked PTH suppression. However, ADMA [Paricalcitol: baseline 0.75 μMol/L (95%CI: 0.70-0.81), 12 week 0.72 μMol/L (95%CI: 0.66-0.78); Placebo: baseline 0.75 μMol/L (95%CI: 0.70-0.90) 12 weeks 0.70 μMol/L (95%CI: 0.66-0.74)] and SDMA [Paricalcitol: baseline 0.91 μMol/L (95%CI: 0.82-1.00), 12 week 0.94 μMol/L (95%CI: 0.82-0.1.06); Placebo: baseline 0.91 μMol/L (95%CI: 0.82-1.06) 12 weeks 0.99 μMol/L (95%CI: 0.88-1.10)] remained unchanged during the trial and 2 weeks after stopping these treatments.

Conclusions: Paricalcitol does not modify plasma ADMA and SDMA in patients with stage 3-4 CKD. The apparent beneficial effects of paricalcitol on ADMA registered in cross-sectional studies is likely attributable to confounding by indication rather than to a true effect of this drug on ADMA metabolism.

Citing Articles

New insight into primary hyperparathyroidism using untargeted metabolomics.

Wielogorska-Partyka M, Godzien J, Podgorska-Golubiewska B, Sieminska J, Mamani-Huanca M, Mocarska K Sci Rep. 2024; 14(1):20987.

PMID: 39251672 PMC: 11385525. DOI: 10.1038/s41598-024-71423-1.

Ventricular arrhythmias in mouse models of diabetic kidney disease.

Laurita K, Khan S, McMahon T, Dennis A, Li V, Gaivin R Sci Rep. 2021; 11(1):20570.

PMID: 34663875 PMC: 8523538. DOI: 10.1038/s41598-021-99891-9.

Serum symmetric dimethylarginine concentration in healthy horses and horses with acute kidney injury.

Siwinska N, Zak A, Slowikowska M, Niedzwiedz A, Paslawska U BMC Vet Res. 2020; 16(1):396.

PMID: 33081772 PMC: 7576750. DOI: 10.1186/s12917-020-02621-y.

Asymmetric (ADMA) and Symmetric (SDMA) Dimethylarginines in Chronic Kidney Disease: A Clinical Approach.

Oliva-Damaso E, Oliva-Damaso N, Rodriguez-Esparragon F, Payan J, Baamonde-Laborda E, Gonzalez-Cabrera F Int J Mol Sci. 2019; 20(15).

PMID: 31357472 PMC: 6696355. DOI: 10.3390/ijms20153668.

References

Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-70. DOI: 10.7326/0003-4819-130-6-199903160-00002. View

Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A . Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn Circ J. 2001; 65(9):775-8. DOI: 10.1253/jcj.65.775. View

Xiao Z, Quarles L, Chen Q, Yu Y, Qu X, Jiang C . Effect of asymmetric dimethylarginine on osteoblastic differentiation. Kidney Int. 2001; 60(5):1699-704. DOI: 10.1046/j.1523-1755.2001.00011.x. View

Napoli R, Biondi B, Guardasole V, Matarazzo M, Pardo F, Angelini V . Impact of hyperthyroidism and its correction on vascular reactivity in humans. Circulation. 2001; 104(25):3076-80. DOI: 10.1161/hc5001.100621. View

Zoccali C, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A . Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2002; 358(9299):2113-7. DOI: 10.1016/s0140-6736(01)07217-8. View

Stuhlinger M, Abbasi F, Chu J, Lamendola C, McLaughlin T, Cooke J . Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002; 287(11):1420-6. DOI: 10.1001/jama.287.11.1420. View

Delles C, Jacobi J, John S, Fleischmann I, Schmieder R . Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Kidney Int. 2002; 61(4):1462-8. DOI: 10.1046/j.1523-1755.2002.00260.x. View

Asagami T, Abbasi F, Stuelinger M, Lamendola C, McLaughlin T, Cooke J . Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism. 2002; 51(7):843-6. DOI: 10.1053/meta.2002.33349. View

Zoccali C, Mallamaci F, Maas R, Benedetto F, Tripepi G, Malatino L . Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 2002; 62(1):339-45. DOI: 10.1046/j.1523-1755.2002.00437.x. View

10.

Lu R, Hu C, Wu X, Liao E, Li Y . Effect of age on bone mineral density and the serum concentration of endogenous nitric oxide synthase inhibitors in rats. Comp Med. 2002; 52(3):224-8. View

11.

Hermenegildo C, Medina P, Peiro M, Segarra G, Vila J, Ortega J . Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients. J Clin Endocrinol Metab. 2002; 87(12):5636-40. DOI: 10.1210/jc.2002-020905. View

12.

Maas R, Schwedhelm E, Albsmeier J, Boger R . The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. Vasc Med. 2003; 7(3):213-25. DOI: 10.1191/1358863x02vm429ra. View

13.

Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus J, Thadhani R . Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003; 349(5):446-56. DOI: 10.1056/NEJMoa022536. View

14.

Selley M . Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiol Aging. 2003; 24(7):903-7. DOI: 10.1016/s0197-4580(03)00007-1. View

15.

Holden D, Cartwright J, Nussey S, Whitley G . Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine. Circulation. 2003; 108(13):1575-80. DOI: 10.1161/01.CIR.0000091083.61609.DF. View

16.

Post M, Verhoeven M, van der Mooren M, Kenemans P, Stehouwer C, Teerlink T . Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women. J Clin Endocrinol Metab. 2003; 88(9):4221-6. DOI: 10.1210/jc.2003-030584. View

17.

Mullender M, El Haj A, Yang Y, van Duin M, Burger E, Klein-Nulend J . Mechanotransduction of bone cells in vitro: mechanobiology of bone tissue. Med Biol Eng Comput. 2004; 42(1):14-21. DOI: 10.1007/BF02351006. View

18.

Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke J . Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med. 2004; 42(12):1377-83. DOI: 10.1515/CCLM.2004.257. View

19.

Fliser D, Kronenberg F, Kielstein J, Morath C, Bode-Boger S, Haller H . Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol. 2005; 16(8):2456-61. DOI: 10.1681/ASN.2005020179. View

20.

Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C . Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol. 2005; 16(8):2449-55. DOI: 10.1681/ASN.2005010076. View